$SYRE News

Spyre Therapeutics Completes Enrollment For All Sub-Studies In SKYWAY Basket Trial Of SPY072 In Rheumatic Diseases

Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms

Spyre Therapeutics Expands SPY003 Rights Beyond IBD Through Amended Paragon License Agreement

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million

Citigroup Maintains Buy on Spyre Therapeutics, Raises Price Target to $97

Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $107

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Spyre Therapeutics Q1 EPS $(0.74) Misses $(0.68) Estimate

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise

Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?

Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers

Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)

Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

Reported Earlier, Spyre Therapeutics Prices Upsized Public Offering Of 6.5M Common Shares At $62.00 Per Share For Gross Proceeds Of $403.0M